In a controversial and divisive article, a group of researchers proposes to improve "statistical standards of evidence" by lowering the P value from P <.05 to P <.005 in the fields of biomedical and social sciences.
Reference values for PROMIS domains have been established by a population-based study.
Standardized and clinically meaningful outcome measures in clinical trials in chronic pain may enhance efforts to develop effective treatments for chronic pain patients.
Researchers identified 3 subgroups of patients with peripheral neuropathic pain, based on sensory signs and symptoms.
Drug development faces 2 major issues: pre-clinical animal efficacy studies do not accurately predict human efficacy, and clinical trials often wrongly fail to show drug efficacy.
Connectivity in the right midfrontal gyrus may help predict placebo response.
Clinical Pain Advisor Articles
- Virtual Reality for Pain Relief: Understanding the Underlying Mechanisms
- Vibrating Gloves Significantly Reduce Osteoarthritis-Related Hand Pain
- Neuroinflammation in Neuropathic Pain Indicated by Elevated Levels of Proinflammatory Chemokines in CSF
- Neuroimaging for Chronic Pain: IASP Consensus Statement
- Hypertension in Chronic Pain: Risk Factors
- Liposomal Bupivacaine Effective for Shoulder Arthroplasty-Related Pain
- Reducing the P-Value for Statistical Significance to Improve the Quality of Research?
- FDA's Strategies for Managing Patients Taking CNS Depressants and Opioids
- Electrotherapy, Acupuncture May Decrease Pain Following Total Knee Arthroplasty
- Low-Dose Oromucosal Ibuprofen Effective for Relieving Sore Throat
- Survey Finds Teens Divided on Beliefs and Attitudes of Prescription Drug Abuse
- HIV-Positive Patients Experience Frequent Headaches
- Low-Dose Perineural Dexamethasone Prolongs Effects of Brachial Plexus Nerve Block
- Business Savvy Tips for Buying a Practice
- Diphenhydramine Decreases Pain During Colonoscopy for Chronic Opioid Users